Pharmaceutical

Illimis secures funding for GAIA-based Alzheimer’s therapeutics

Illimis has completed a Series B funding round, securing $42m for the development of its GAIA-based Alzheimer's disease therapeutics.

Jul 15, 2025 - 06:00
Illimis secures funding for GAIA-based Alzheimer’s therapeutics
Illimis has completed a Series B funding round, securing $42m for the development of its GAIA-based Alzheimer's disease therapeutics.
Read the original article

Tags:

Previous Article

Scaling smart: how small pharma companies can build resilient supply chains

Next Article

GSK eyes FDA label expansion for RSV vaccine Arexvy to include younger patients

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

The Genomic Medicine Revolution: Multi-Modality Approaches in Advanced Therapies 

The Genomic Medicine Revolution: Multi-Modality Approac...

Aug 17, 2024

Podcast: AI and Supervised Machine Learning in Clinical Trials – Part 2

Podcast: AI and Supervised Machine Learning in Clinical...

Jun 11, 2025

Gates Foundation to fund trial of long-awaited new tuberculosis vaccine candidate

Gates Foundation to fund trial of long-awaited new tube...

Jun 28, 2023